Key result
Elevated MMP-2 in pediatric CKD is independently associated with increased arterial stiffness in hypertensive patients.
Why the study?
Matrix metalloproteinases may contribute to arterial stiffness through extracellular matrix remodeling, prompting evaluation of MMP-2 and MMP-9 levels and their associations with cardiovascular risk factors and arterial stiffness markers in children with CKD or type 1 diabetes.
Are serum MMP-2 and MMP-9 levels elevated and associated with arterial stiffness (cfPWV and AIx75) and cardiovascular risk factors in children and adolescents with chronic kidney disease or type 1 diabetes compared to healthy controls?
Cross-Sectional (n=75)
No
Are serum MMP-2 and MMP-9 levels elevated and associated with arterial stiffness (cfPWV and AIx75) and cardiovascular risk factors in children and adolescents with chronic kidney disease or type 1 diabetes compared to healthy controls?
In pediatric patients, serum MMP-2 is elevated in CKD (but not in uncomplicated type 1 diabetes), correlates independently with serum phosphate, and associates with increased arterial stiffness (cfPWV) specifically when hypertension coexists.
Answers are grounded in this paper and cite their sources.
MMP-2 elevation may flag arterial stiffness risk in hypertensive CKD youth; leaves open prognostic value and therapeutic targeting.
Matrix metalloproteinases (MMPs) may contribute to the pathogenesis of arterial stiffness inducing extracellular matrix remodeling. We aimed to compare MMP-2 and -9 levels in children with chronic kidney disease (CKD), type 1 diabetes (without chronic kidney disease) and healthy control and to investigate associations of MMPs levels with cardiovascular risk factors and markers of arterial stiffness. The study population included 33 CKD, 18 type 1 diabetes patients, and 24 healthy controls. MMP-2, MMP-9, office blood pressure, pulse wave analysis, and carotid-femoral pulse wave velocity (cfPWV) measurements were performed. MMP-2 levels were higher in the CKD compared to the diabetes and control groups (p < 0.05). MMP-9 levels did not differ among groups. In hypertensive individuals logMMP-2 independently associated with PWV z score (β = 0.744, 95%CI 0.105 to 2.921, p < 0.05) after adjustment for age, sex, GRF, and phosphate levels. Creatinine levels correlated positively with MMP-2 in the CKD (r = 0.39, p < 0.05) and negatively in the diabetes group (r = −0.72, p < 0.05). Cholesterol levels correlated with MMP-2 in the diabetes group (r = 0.70, p < 0.05). Phosphate levels correlated with MMP-2 level in the control group (r = 0.67, p < 0.05). In multivariate regression model adjusted for age and sex, including phosphate and GRF as covariates, only phosphate predicted logMMP-2 levels (β = 0.333, 95%CI 0.060 to 0.671, p < 0.05). MMP-2 associated with arterial stiffness in the presence of hypertension, while the role of MMP-9 is less clear in children with CKD or type 1 diabetes. Whether up-regulation of MMPs could predict poor outcomes in young high-risk patient groups need to be confirmed by future studies.
No takes yet. Share an insight, caveat, or question.
Stabouli et al. (2020) conducted a cross-sectional in Pediatric chronic kidney disease (CKD) and type 1 diabetes (n=75). Chronic kidney disease, type 1 diabetes, and serum MMP-2 / MMP-9 levels vs. Healthy pediatric controls (n=24) was evaluated on Serum MMP-2 levels (ng/mL) and carotid-femoral pulse wave velocity (cfPWV) z-score (β = 0.744 (logMMP-2 with PWV z-score in hypertensive individuals), 95% CI 0.105 to 2.921, p=<0.05). Serum MMP-2 levels were elevated in children with CKD and independently associated with PWV z-score in hypertensive subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: